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Biologically based treatment planning is a broad term used to cover any instance in
radiotherapy treatment planning where some form of biological input has been used. This
is wide ranging, and the simpler forms (e.g., fractionation modification/optimization) have
been in use for many years. However, there is a reluctance to use more sophisticated
methods that incorporate biological models either for plan evaluation purposes or for
driving plan optimizations. This is due to limited data available regarding the uncertainties
in these model parameters and what impact these have clinically. This work aims to
address some of these issues and to explore the role that uncertainties in individual
model parameters have on the overall tissue control probability (TCP)/normal tissue
control probability (NTCP) calculated, those parameters that have the largest influence
and situations where extra care must be taken. In order to achieve this, a software
tool was developed, which can import individual clinical DVH’s for analysis using a
range of different TCP/NTCP models. On inputting individual model parameters, an
uncertainty can be applied. Using a normally distributed random number generator,
distributions of parameters can be generated, from which TCP/NTCP values can be
calculated for each parameter set for the DVH in question. These represent the spread
in TCP/NTCP parameters that would be observed for a simulated population of patients
all being treated with that particular dose distribution. A selection of clinical DVHs was
assessed using published parameters and their associated uncertainties. A range of
studies was carried out to determine the impact of individual parameter uncertainties
including reduction of uncertainties and assessment of what impact fractionation and
dose have on these probabilities.
Keywords: normal tissue complication probability (NTCP), tumor control probability (TCP), uncertainty, biologically
based treatment planning, biological optimization
INTRODUCTION
Radiobiology has played a critical role in clinical radiotherapy for many years, and it is common
practice to use radiobiological methods, for example, to account for different fractionation
regimes and modalities in combined treatment (such as combined external beam radiotherapy
and brachytherapy in gynecological treatments) (1) and to account for interruptions in treatment
(2). Following the significant technological development of the last decade, which has resulted
in a variety of methods for the delivery of precise radiation doses, there is now a drive
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to implement radiobiological methods in either the evaluation
of treatment plans (for plan comparison for an individual
patient) or for triaging patients who would benefit from more
advanced radiotherapy techniques, e.g., protons (3) or the actual
optimization of plans. Moreover, the use of radiobiological
models for treatment plan optimization is an important first
step for the development of truly personalized radiotherapy.
This would allow full exploitation of the therapeutic power of
radiation and the advances in genomic testing while safeguarding
the more radiosensitive individuals.
The Task Group document from the AAPM, report 166 (4,
5) provides an outline describing biologically based treatment
planning including descriptions of commonly used models and
how different treatment planning systems (TPS) implement
these. They also provide guidelines for implementation and
quality assurance (QA) of such systems and vision for the
future. A coherent explanation of the different levels of biological
optimization was described by Nahum et al. (6). They outlined
the different levels, which ranged from very simple methods
(level 1) included in trials, such as IDEAL-CRT and I-Start,
which individualize/escalate prescription levels based on organ
at risk dose, to level 5, where they envisage such techniques being
employed that would take into account a patient’s individual (not
based on population data) biology. The different levels coined
by Nahum et al. are paraphrased from the original publication
(6) below. The reader is directed to their publication for further
details on this subject.
Level 0: no biological optimization.
Level I: individualization of prescription dose for specified
level of toxicity [i.e., dose escalated in plans where
possible using fixed normal tissue control probability
(NTCP) level for the organ at risk (OAR)].
Level II: the same as above, but the number of fractions is
adjusted as well as the prescription dose based on an
isotoxic basis.
Level III: biological cost functions used in the actual
optimization of the dose distribution. Equivalent
uniform dose (EUD), TCP, and NTCP parameters are
used alongside conventional DVH parameters used in
the optimization (e.g., Dmax, D99, V50%, mean).
Level IV: individual patient-specific data is used in the
optimization of the patient’s plan (e.g., use of
functional imaging to highlight areas of hypoxia and
other areas of increased radio-resistance).
Level V: using individual patient biology to optimize dose
prescriptions in conjunction with any of the
other levels.
We are currently at, or are approaching, level III where TPS
are now incorporating biological models for either evaluation
or optimization purposes. One of the benefits in using TCP
or NTCP models is that a single value can be used in place
of an array of dosimetric parameters describing points along
a DVH curve. However, it is critical to assess the uncertainty
affecting such values and what the key elements underpinning
such uncertainty are. Different companies and TPS systems
employ different formalisms and algorithms despite adopting
the same radiobiological models, resulting in fundamental
differences for the final calculations of the TCP/NTCP values
and related uncertainties. An accurate understanding of how
the uncertainties associated with the input parameters impact
the final NTCP or TCP values is paramount and will support
the increasing use of such approaches in planning radiotherapy
treatments. Moreover, understanding how uncertainties are
propagated in the TCP and NTCP calculations will identify the
input parameters, which will need to be better defined along
with their acceptable level of uncertainty to guide pre-clinical
research efforts.
The aim of this study was to assess the impact of uncertainties
in individual parameters used in TCP/NTCP calculations. This
was achieved using in-house software developed in MATLABTM
vR2017a (The MathWorks Inc., MA, USA) that generates a
simulated population of parameters within the constraints of
the input parameters and their uncertainties, from which TCP
or NTCP values and their uncertainties can be calculated. Dose
is supplied using the 1D dose distribution as described by the
planning DVH for the structures in question. The simulated
data is generated using MatLabTM’s normally distributed random
number generator. A set of values are generated that are normally
distributed with a mean, standard deviation, and size as specified
by the user. The impact from single-parameter and multiple-
parameter uncertainties was assessed for a range of clinically
acceptable prostate plans, focusing on both survival probability
and the probability of rectal complications. A similar approach
was taken by Zhang et al. (7) for epithelial pleural mesothelioma
where they applied an uncertainty to either the alpha term for the
TCP model used (8) or the D50 parameter of the NTCP model
used, the Lyman Kutcher Burman (LKB) model (9–12). This
was to simulate heterogeneity in radiosensitivity of a population
over a set dose range and focusing on therapeutic ratio for the
prescription dose set. Our approach used uncertainties in all
model input parameters and was focused not on a prescription
dose but the planned organ doses (physical and biological)
from clinical plans. No uncertainty was applied to the dose;
however, there was a natural variation in doses as a result of the
uncertainties applied to those parameters used in the biological
dose calculation. The resulting dose (for the rectum especially)
was very specific to the individual anatomy and the resulting
plan generated. Plans were selected to represent the full range of
possible doses that might be encountered.
The data reported show how the proposed approach can
quickly generate uncertainty levels for TCP and NTCP models
(for individual dose distributions as calculated by a treatment
planning system for clinically acceptable plans) taking into
consideration the uncertainties in the input parameters. The
approach was tested for the specific case of prostate treatment
and using the Lind (13) and LKB (9–12) models for TCP
and NTCP, respectively, and highlighted the key role that the
D50 parameter plays in the overall uncertainties. The study
also indicates a strong synergy between the input parameters
with small uncertainties on a single parameter having an
overall large effect on the variation in the TCP/NTCP values
generated when combined with uncertainties from the other
parameters. The approach can be considered a first step in the
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robustness validation of radiotherapy treatment planning based
on biological optimization.
METHODS
Software
Software was developed in MATLAB, which allowed the import
of dose volume histograms from clinical plans from different
TPS. Different input formats available were for DVHs from
BioSuite© (13), EclipseTM, PinnacleTM, and RaystationTM. Dose
and volume data were processed to allow the visualization of
both cumulative and probability density histograms of the data.
Using the linear quadratic formula, dose was converted into
the equivalent dose if the treatment was given in 2Gy fractions
(LQED2) (14, 15) using the alpha/beta ratio (α/β) and the
number of fractions as supplied by the user (see Equation 1).
The α/β ratio is from the linear-quadratic relationship between
cell survival and irradiated dose, Di is the total dose per DVH
dose-bin, and n is the number of fractions.
LQED2i =
1+ Di/n
α/β
1+ 2
α/β
(1)
It is possible, in the software, to incorporate an uncertainty
on the α/β value entered. This is used to generate a normally
distributed virtual distribution of alpha and beta parameters.
This is done using the normally distributed random number
generator in MatLabTM, which generates a distribution of values
of size n. The values are generated such that they have a mean
and standard deviation that matches that supplied by the user.
Using these parameters, simulated variations in the LQED2 are
calculated. After calculation of the LQED2 variations for a DVH,
the required radiobiological models can be selected for the TCP
and NTCP analysis.
The TCP model used for this study was Lind’s model (16).
Equation (2) shows the model formula as displayed in AAPM
report 166 (4) for use with doses converted into LQED2 using
Equation (1). The γ parameter is the slope parameter, D50 is
the dose at which there is a 50% probability of tumor control
occurring, and Di and vi are dose-bin values and corresponding
fractional volume obtained from the DVH, respectively.
P (Di) = exp
(
−exp
(
eγ − Di
D50
(
eγ − ln (ln2))))
TCP =
M∏
i = 1
P (Di)
vi (2)
The NTCP model used in this study was the LKB model (9–12)
(see Equations 3–5), where effective dose (Deff) is the uniform
dose, which gives the equivalent biological effect to the structure
in question as the planned inhomogeneous dose distribution
from the DVH. The volume parameter n describes how serial
or parallel an organ is. Di and vi are dose-bin values and
corresponding fractional volume obtained from the DVH. The m
parameter describes the slope of the NTCP vs. dose relationship,
and D50 is the dose at which 50% chance of complications
occur. Similar to what was described for the α/β uncertainty,
uncertainties in all the above user input parameters (i.e., D50, m,
n) can be provided and are propagated to the final NTCP value
calculated. TCP/NTCP values are collected for each simulation
and the standard deviation calculated as a measure of the
propagated uncertainty.
NTCP = 1√
2pi
∫ t
−∞
e
x2
2 dx (3)
t = Deff − D50
mD50
(4)
Deff =
(∑
i
viD
1/n
i
)n
(5)
Input Parameters
DVHs from a selection of clinically acceptable prostate plans
were used for this study. The conventional vs. hypofractionated
high-dose intensity-modulated radiotherapy for prostate cancer
(CHHIP) trial (17) planning constraints were used, and the
prescription was either 74 or 78Gy to allow a range of doses
(and, therefore, positions on the TCP curve) to be evaluated.
The input parameters investigated were taken from the literature.
Initial study parameters for rectal toxicity were from Lyman et al.
(10): D50 = 7,500 cGy, m = 0.1, n = 0.1, and α/β = 300 cGy. A
study from Marzi et al. (18) was used for the later analysis as this
study provided uncertainty values with its published parameters.
Parameters used were for the prediction of greater than, or equal
to, G2 late toxicity of the rectum; D50 = 7,600 ± 190 cGy, α/β
= 230±60 cGy, n = 0.12, and m = 0.15 (no uncertainties were
provided for the n and m parameters). The TCP values used for
the prostate PTV analysis were from Okunieff et al. (19) for T2
multi-institute macroscopic disease; the slope parameter γ was
used for the slope parameter γ in the Lind formulism, γ = 1.16
and D50 = 4,518 cGy. Data from the CHHIP trial (17) was used
for the prostate α/β parameter: α/β= 180 cGy.
Analysis 1
For the first analysis, the uncertainty in each parameter was
progressively increased to determine its specific impact on
the final probability calculated. The analysis was performed
by varying the uncertainty on one parameter at a time while
assuming no error on the other parameters. This was carried
out for both NTCP and TCP models investigating the rectum
and for the prostate PTV. Analysis was performed using Lyman
and Okunieff parameters for the NTCP and TCP calculation,
respectively. For each model, in turn, and for each associated
parameter, in turn, the MatLab code allowed simulated sets
of parameters to be generated. These sets of input parameters
were simulated such that the mean and standard deviation
were as specified by the user. Using each value, in turn,
from the simulated parameter set, an NTCP or TCP value
was then calculated. Finally, a mean and standard deviation
was calculated over the probabilities (either NTCP or TCP)
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FIGURE 1 | Data collected for Analysis 1, normal tissue control probability (NTCP) calculations using the Lyman Kutcher Burman (LKB) model for the rectum. (A–C)
The impact on the overall NTCP uncertainties as a result of increasing uncertainty in the individual parameters. Values used for α/β, n, D50, and m were 300 cGy, 0.1,
7,500 cGy, and 0.1, respectively, and the uncertainties applied are expressed as a fraction of each parameter. (D) shows the relationship between Deff (as a fraction of
the D50) and the uncertainty in the final NTCP calculated for different levels of uncertainty in the D50 parameter; lines are for guiding the eye only.
calculated for an individual user-defined set of parameters and
associated uncertainties.
Analysis 2
The second analysis involved using the Marzi parameters and
uncertainties for calculating the NTCP for late rectal toxicity with
the aim of determining the impact of such clinically acceptable
values in the final probability calculated. For this analysis, all the
reported uncertainties were simultaneously considered.
RESULTS
Figures 1A–C report how the uncertainties in the calculated
NTCP values varies as a function of the uncertainties of the input
parameters for three clinically approved treatment cases with
different Deff doses. Figure 1D shows how theDeff as a percentage
of theD50 parameter varies with uncertainty inNTCP for the four
patient cases investigated. The different curves represent different
levels of uncertainty applied to the D50-simulated parameter
sets. For all cases, the uncertainty in the NTCP calculation is
dominated by the uncertainty in the D50 parameter, and it follows
a similar trend with its value initially increasing exponentially
to then reaching a plateau (NTCP uncertainty ∼42%) for D50
uncertainties >40%. There is an almost immediate increase in
NTCP uncertainty for the patients with the higher Deff, while a
slight lag is observed for the lowest Deff patient. A similar trend
is observed for the NTCP uncertainty as a function of the m
parameter, although the impact is much smaller than for the D50
parameter. Interestingly, the other parameters (including the α/β
ratio) play a much smaller role contributing at most 15% of the
NTCP uncertainty for 100% uncertainty in the input parameter.
The uncertainty in the α/β ratio had the least impact on the
overall uncertainty in NTCP. Only the patient with the very
highest Deff showed a significant increase in NTCP uncertainty
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FIGURE 2 | The relationship between the uncertainty in n (A) and m (B) with the overall uncertainty in the NTCP calculated for a selection of patients with ranging
values of rectum Deff. Values used for α/β, n, D50, and m were 230 ± 60 cGy, 0.12, 7,600 ± 190 cGy, and 0.15, respectively (18). The uncertainties applied are
expressed as a fraction in question and uncertainties are applied to either n or m individually with an uncertainty of zero used for the parameter not being assessed.
but that was small and not observed until the uncertainty in α/β
reached 40%.
Considering the critical effect of Deff, the uncertainties in the
NTCP have been reported as a function of the Deff/D50 ratio
for different D50 uncertainties in Figure 1D. The data highlight
how, for low Deff plans, the uncertainty in NTCP are quite
small irrelevant of the uncertainty in all the input parameters.
However, as Deff approaches 80% of the D50 value, the inaccuracy
in determining the D50 has a major impact on the NTCP
uncertainty. From Figure 1, it also emerges that an uncertainty of
D50 < 6.7%would be required tomaintain the NTCP uncertainty
<5% irrespective of the Deff values. The only exception is patient
4 (uncertainty in NTCP of 6.9%); however, this patient is at the
upper limit of what would be accepted clinically for rectal doses.
In order to appreciate the level of uncertainties, which
commonly affect clinically relevant NTCP estimations, the data
set from Marzi et al. was used on the four patient cases
highlighted above. This data set was selected as it investigated
NTCP for a relevant biological endpoint and was one of the
fewer studies quoting uncertainties on input parameters, 2.5 and
26% for D50 and α/β, respectively. Without further uncertainty
considerations for the other parameters, the overall NTCP
uncertainties calculated through the simulation approach are
of the order of 2% for all cases investigated (Figure 2). This
is significantly lower than the uncertainty that would result
from a simple relative error propagation (i.e., square root of
the sum of the individual relative errors squared), which would
be dominated by the error in the α/β resulting in the overall
uncertainty for the NTCP values of ∼26%. Moreover, the
impact of uncertainties in the n or m parameters (the former
in particular) become quickly significant pushing the NTCP
uncertainty up to ∼10% for an input parameter error of 40%
[Figures 2A (n), B (m)]. The effect was again more pronounced
for patients with high Deff. For small uncertainties in m or n, the
uncertainty in NTCP derives mainly from the D50 uncertainty,
and the differences in the uncertainties between the patients are
a consequence of the different Deff values.
As expected, the uncertainties in the input parameters
combine for the overall NTCP calculations. For the patient with
the highest Deff, a D50 uncertainty alone of 2.5% (as for the Marzi
data set) would result in an NTCP uncertainty of 1.9%, which
remains the same when combined with the uncertainty in α/β
(up to ∼26%). With a 26% uncertainty in the α/β alone, the
uncertainty in the final NTCP parameter is 0.3% confirming that
D50 is the dominant source of uncertainty where the fractionation
regime is at, or close to, 2 Gy/fraction. This clearly shows that
impact of the individual parameters is not linear with regard to
uncertainty propagation.
In order to better appreciate the interlink between the input
parameter uncertainties, variation in the NTCP values have
been simulated for the four different clinical cases assuming
uncertainties on all the parameters simultaneously. The Marzi
data set was again used as starting point, and errors of ∼7
or ∼20% were added to both the n and m parameters. Data
in Figure 3A (no uncertainty on m or n) clearly show the
impact of uncertainty in the D50 and α/β on the NTCP values
with minimum effect on the Deff. It is also interesting to
notice how the NTCP values are not symmetrically distributed
around the NTCP curve but stretched toward the high NTCP
values. This would have strong consequences for the setting
of NTCP acceptance levels for a population case. The addition
of uncertainties in the n and m parameters (see Figures 3B,C)
increases the Deff values moving the calculations toward the
steeper part of the NTCP curve resulting, therefore, in higher
NTCP values. While an individual ∼20% uncertainty in the n or
m parameters had only a small effect on the NTCP uncertainty
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FIGURE 3 | (A) The NTCP vs. Deff curve for grade 2 late toxicity of the rectum (18). Values used for α/β, n, D50, and m were 230 cGy, 0.12, 7,600 cGy, and 0.15,
respectively. Simulated rectum NTCP values for a selection of patients with uncertainties of 60 and 190 cGy applied to α/β and D50 parameters, respectively, have
been plotted onto the curve for a selection of patients with different Deff. Each point represents one simulation. (B,C) The simulated results when an additional
uncertainty is applied to both m and n of 0.1 (B) and 0.3 (C).
when D50 ∼2.5% (Figures 3A,B), their combined effect pushes
the NTCP values from <15% up to 40% despite a still low
D50 uncertainty (Figure 3C). Therefore, when considering the
combined uncertainties, it is important to keep the uncertainty
in the m and n parameters below 0.3 for both parameters.
For a greater understanding of the overall picture, the range in
the NTCP values calculated was also evaluated. The NTCP range
without uncertainties applied to them and n parameter was 0.03–
0.21. This range increases to 0.01–0.21 for an uncertainty of 0.1
in m and n and then to 0–0.37 for an uncertainty of 0.3. This
demonstrates a clear benefit in keeping the uncertainty for such
parameters in the lower range (around the 0.1 mark) where the
influence of these parameters is low.
Interestingly, a conventional error propagation approach
would result in an average NTCP uncertainty of ∼28% for the
input parameter set: D50 = 7,600 ± 190, α/β = 230 ± 60, n
= 0.12 ± 0.01 and m = 0.15 ± 0.01, while the simulation
approach estimates an uncertainty of ∼40% for the selected
patients. The average NTCP values also change when accounting
for uncertainties using the simulation approach due to the low-
level boundary of NTCP = 0 and the data spread, which pushes
the NTCP values up. Table 1 shows the difference in the NTCP
values and their related uncertainties comparing a conventional
error propagation method to the simulation approach.
A similar approach has been also used to investigate the
impact of the input parameter uncertainties on the TCP
calculations (see Figures 4A,D). Each input parameter was
individually considered for the four cases used so far and
the relationship between uncertainty in TCP plotted against
the uncertainties applied to the individual input parameters.
The PTV was used as opposed to the prostate volume due
the availability of data. For the one patient data set where
both PTV and prostate volume were present, an analysis was
performed with both structures, and data were very similar
(see Figures 4A,B). D50 again appeared to be the most critical
parameter, however, following a more linear response than
for the NTCP investigations. The relationship between TCP
TABLE 1 | Table showing the differences in both mean and uncertainty (standard
deviation expressed as a percentage of the mean) for different methods of error
propagation calculation, the conventional numerical method, and the simulated
method discussed in this manuscript.
Conventional error propagation Simulation approach
NTCP Error [%] NTCP Error [%]
Patient A 0.0733 28 0.0761 32
Patient B 0.0535 28 0.0557 36
Patient C 0.0367 28 0.0391 41
Patient D 0.0040 28 0.0046 63
and uncertainty in parameter appeared to be almost linear for
all parameters and almost identical for all Deff analyzed. The
relationship D50 vs. TCP uncertainty showed a slight benefit for
the higher dose structures (see Figure 4D). From the limited
range of cases investigated, uncertainty levels <10% for D50
would be required to achieve TCP uncertainties<5%. This could
also be of importance when considering co-factors, e.g., clinical
factors such as age, concurrent chemo, prior surgery, etc. A study
on the impact of co-factors (20) dealt with differences in response
through the D50 parameter. Using an uncertainty analysis such as
described could be used clinically to define a level (uncertainty in
D50) at which it is appropriate to separate sub-groups out of a
main group.
Uncertainties in the α/β parameter appear to have a negligible
impact on the TCP uncertainty for the Lind model. This is due
to the fractionation regime used and the fact that the influence of
the α/β ratio is in converting from physical dose into LQED2.
Owing to the fact that most of the voxels in the PTV will
be receiving a fractionation of very close to 2Gy per fraction,
physical dose is almost identical to LQED2, which means that
the parameter has very little impact on the structure dose being
evaluated with this model. The only response observed were for
patients B and C, where there was a small impact on NTCP
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FIGURE 4 | Data collected for Analysis 1, tissue control probability (TCP) calculations using the Lind model for the prostate (A,B) and the prostate PTV (C,D). Panels
show the impact on the overall TC value as a result of increasing individual parameters. Values used for α/β, D50, and m were 180 cGy, 4,518 cGy, and 1.16,
respectively, and the uncertainties applied are expressed as a fraction of each parameter.
uncertainty after an uncertainty in the parameter of greater
than 0.5. These patients had the highest Deff and, therefore,
the highest dose per fraction (∼2.2 Gy/fraction), which is the
farthest dose/fraction from 2Gy, which is the fractionation
that LQED2 is referenced to. While the behavior observed
with these test cases would hold true for a large majority of
treatments, it would not be the case for all. With the move
towardmore biologically driven treatments [e.g., use of biological
treatment volume (BTV) and also dose escalation to parts of the
tumor] (21), far less homogenous treatments are used with large
variations in dose across the PTV; these could exceed 130%. In
such cases, not all voxels within the PTV will have doses at, or
around, 2 Gy/#, and this will influence the impact of alpha-beta
ratio uncertainty.
Figures 5A–C show the shape of the TCP curve using prostate
tumor parameters from Okunieff et al. (19). Similar to the NTCP
analysis, uncertainties of 2.5 and 26% were applied to D50 and
α/β, respectively, and the simulated data were plotted on the
graph. Uncertainties of 0, 0.1, and 0.3 were applied to the m
parameter and are shown in Figures 5A–C, respectively. A value
of −10 was selected for the “a” parameter to convert the DVH
dose into an equivalent uniform dose (EUD), which is identical to
Deff, with n= 1/a. This value is widely used for tumor structures,
and due to the fact that the variation in the dose distribution
(from the DVH) for the structure is low (1% variation), it was
thought to be an appropriate choice (22). Of course, in cases
where there is dose escalation in the PTV, an appropriate value
for the parameter “a” would have to be consideredmore carefully.
There is little spread in the x-direction axis due to the fact
that the only parameter with influence on dose is the α/β. As
mentioned earlier, where the fractionation regime is close to a
standard one delivering 2 Gy/fraction, the α/β has little impact
on the resulting LQED2Gy calculated. Patients C and D have
the largest spread because their dose/fraction is farthest away
from the standard 2 Gy/fraction. However, while their x-axis
uncertainty is larger, the overall uncertainty in the TCP is lower
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FIGURE 5 | The solid line shows the TCP vs. Deff curve for the prostate using values of 180 cGy, 4,518 cGy, and 1.16 for a/b, D50, and m respectively (18). Simulated
prostate TCP values for a selection of patients with uncertainties of 47 cGy (26%) and 113 cGy (2.5%) applied to a/b and D50 parameters, respectively, have been
plotted onto the curve for a selection of patients with different Deff. (A) Shows no uncertainty applied to m for the simulated patients and (B,C) show uncertainties in m
of 0.1 and 0.3 respectively. Deff for each simulation was calculated using the generalized equivalent uniform dose (EUD) formula, with parameter a set to –10.
(3.5% for Patient C compared with 4.4% for Patient D for an
uncertainty in γ of 30%), which is in keeping with the relationship
shown in Figure 4D, where the higher-dose PTVs benefit from
slightly improved uncertainties in TCP for different levels of
uncertainty in the D50 parameter. As for the NTCP data, the
combined effect of uncertainties in the input parameters quickly
results in a significant increase in the TCP range. The TCP
value range using an uncertainty in γ of 30% is high (∼48 to
99%) compared to a range of 88 to 96% for 0 uncertainty in γ,
which increases to 85 to 97% for uncertainty in γ of 10%. While
the actual TCP uncertainty (calculated as standard deviation of
the probability data collected) is under 5% for all patients, the
spreading of the range data shows a clear benefit (similar to
the LKB for the NTCP data) of keeping uncertainties in the γ
below 10%.
There was a dose effect with structures having Deff or EUD
at the periphery of the slope, having smaller uncertainty than
those nearer the center of the curve. This is due to the fact that
positions on the curve that are at the start or end of the curve are
on a shallower gradient and, therefore, less impacted by changes
in the slope. This software can be used as a tool to highlight
where models maybe susceptible to steep increases in uncertainty
size, e.g., for LKB, there are certain boundaries around which
you may need to be especially careful; however, for the Lind
model, there seems to be an almost linear increase in uncertainty
in TCP for increasing uncertainty of the input parameters.
The analysis also indicates the desired level of uncertainty for
the input biological parameters in order to obtain TCP/NTCP
values with reasonable confidence intervals. Such information
can be used to focus future research efforts and improve
estimation of biological parameters, which play a key role in
TCP/NTCP models.
CONCLUSION
We have developed software, which allows an estimation of
the uncertainty associated with TCP/NTCP predictions. The
approach can provide insight on the uncertainty associated with
TCP and NTCP calculations as a function of the uncertainty
for the biological input parameters, the patient specific anatomy
and the treatment dose. The software has been used to identify
the dominant parameters (D50 for both models tested) with
respect to uncertainty propagation. A conventional basic error
propagation approach was also carried out, and it appeared to
underestimate the error in the final NTCP/TCP values suggesting
that different approaches should be considered. Owing to the
fractionation regime of the treatment plans used for the study,
there was little impact from the α/β parameter. For future work,
there is a need to evaluate the impact for cases where the
fractionation regime is significantly different, e.g., CHHIP trial
and also in cases where inhomogeneous dose distributions are
delivered to the PTV. This could soon be the norm especially now
that imaging modalities are in place to identify such areas within
the PTV with, e.g., increased radiosensitivity, increased clonogen
density, and areas of increased hypoxia that would benefit from
escalated doses. As we are moving into an era of highly conformal
treatment planning, dose escalation, and novel approaches, such
as dose painting, including radiobiological guidance as part of
the optimization process, has been proposed to help inform
the evaluation of the trade-off between tumor control and
normal tissue toxicity (21, 23–25). Including uncertainty will
allow evaluation and optimization of the robustness of plans
to biological variations. Similarly, the algorithm can be used
as a useful tool to compare radiobiological models both in
terms of sensitivity and, through application to clinical studies,
accuracy and guide further developments. The present approach
estimates the errors on the NTCP/TPC values by simulating a
random population of input parameters uncorrelated but each
with constrains of their individual uncertainties. Future work
will look at the inter-dependency of input parameter errors
using Bayesian approaches. An additional useful feature to
include in this software would be to incorporate an uncertainty
in the dose itself. Currently, the software only looks at the
probability in input parameters; however, there is an uncertainty
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on dose from many contributing factors. It would be useful
to be able to characterize the uncertainty in the DVH and
incorporate dose uncertainties in the TCP/NTCP uncertainties.
Finally, the study will also be extended to allow analysis of
data from other TCP and NTCP calculations that incorporate
the α/β directly into the models to a greater extent and not
just through converting physical dose to LQED2, e.g., the
Webb model (22).
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